Open in Screener

SAVA

Cassava Sciences Inc

Oct 07 • 09:30AM ET

3.48

-0.09 -2.52 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY AVXL SRPT ANVS ACLX PRTA AXSM FATE XERS

| Held by: VTI VXF IWC VHT AVSC BTEC IBRN MSSM

Index	-	P/E	-	EPS (ttm)	-2.56	Insider Own	13.62%	Shs Outstand	48.31M	Perf Week	19.59%
Market Cap	168.11M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	4.10%	Shs Float	41.72M	Perf Month	62.62%
Enterprise Value	55.73M	PEG	-	EPS next Q	-0.27	Inst Own	25.35%	Short Float	14.12%	Perf Quarter	58.90%
Income	-123.17M	P/S	-	EPS this Y	-32.19%	Inst Trans	-9.19%	Short Ratio	2.85	Perf Half Y	165.65%
Sales	0.00M	P/B	1.91	EPS next Y	39.90%	ROA	-65.00%	Short Interest	5.89M	Perf YTD	47.46%
Book/sh	1.82	P/C	1.50	EPS next 5Y	-	ROE	-88.95%	52W High	33.98 -89.76%	Perf Year	-87.09%
Cash/sh	2.33	P/FCF	-	EPS past 3/5Y	-21.17% -40.61%	ROIC	-140.01%	52W Low	1.15 202.61%	Perf 3Y	-91.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.64% 9.63%	Perf 5Y	-69.77%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-553.86%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-73.13%
Dividend Ex-Date	Dec 13, 2012	Quick Ratio	2.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	67.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	-787.31%	SMA20	25.11%	Beta	-1.11	Target Price	8.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	41.81%	Rel Volume	1.23	Prev Close	3.57
Employees	30	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	SMA200	55.41%	Avg Volume	2.07M	Price	3.48
IPO	Jul 14, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	127,325	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-08-24	Upgrade	H.C. Wainwright	Neutral → Buy	$116
Jul-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral	$44
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$100
Jul-07-21	Reiterated	Maxim Group	Buy	$80 → $190
Apr-27-21	Initiated	B. Riley Securities	Buy	$78
Feb-16-21	Reiterated	H.C. Wainwright	Buy	$20 → $66
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$24
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy	$20
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy	$3 → $12

Show Previous Ratings

Sep-24-25 04:58AM	Cassava, Accenture to deploy sovereign AI solutions across Africa (Verdict)
Sep-23-25 12:13PM	Cassava Boss Buys Big As Stock Collapses (GuruFocus.com) +46.98%
Aug-25-25 08:00AM	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 07:30AM	Cassava Reports Q2 2025 Financials Results and Provides Business Update (GlobeNewswire) +5.70%
Aug-07-25 07:30AM	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer (GlobeNewswire) -6.41%
07:30AM	Loading…
Aug-04-25 07:30AM	Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy (GlobeNewswire) +8.02%
Jun-30-25 07:00AM	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting (GlobeNewswire)
May-08-25 08:00AM	Cassava Reports Q1 2025 Financials Results, Provides Business Update (GlobeNewswire) +8.97%
May-01-25 07:30AM	Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
07:30AM	Cassava Appoints Angelique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
Apr-21-25 04:30PM	Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development (GlobeNewswire) +8.90%
Apr-01-25 09:35AM	Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround (Zacks) -8.00%
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks) -9.09%
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks) -7.89%
07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
08:05AM	Loading…
Mar-25-25 08:05AM	Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (GlobeNewswire) -32.14%
Mar-20-25 06:18PM	Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments (SeekingAlpha)
Mar-05-25 11:20AM	H.C. Wainwright focused on what results from Cassavas ReFocus-ALZ might reveal (TipRanks)
Mar-03-25 07:30AM	Cassava Sciences Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Cassava Sciences Licenses Simufilam Method of Treatment Patent (GlobeNewswire) +13.04%
Jan-16-25 01:56PM	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-13-25 12:15PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-07-25 04:30PM	Cassava Sciences Provides a Business Update (GlobeNewswire) -6.46%
Dec-27-24 05:45AM	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA (PR Newswire)
Dec-16-24 02:55PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky for More Information SAVA (GlobeNewswire)
Nov-25-24 04:15PM	Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops (Investor's Business Daily) -83.78% -10.94%
03:57PM	Cassava Sciences plummets over 80% on Alzheimer's trial fail (Yahoo Finance Video)
09:19AM	Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study (Investopedia)
07:30AM	Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints (GlobeNewswire)
Nov-24-24 08:01PM	Cassava Sciences to Hold Corporate Update on November 25th (GlobeNewswire)
08:30AM	Loading…
Nov-18-24 08:30AM	Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer (GlobeNewswire)
Nov-07-24 07:55AM	Cassava Sciences Reports Q3 2024 Financial and Operating Results (GlobeNewswire)
Oct-31-24 08:30AM	Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 (GlobeNewswire)
Oct-17-24 09:19PM	Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge (Insider Monkey)
Oct-09-24 08:29AM	Cassava Sciences Advances Alzheimers Trials Amid SEC Settlement (TipRanks)
Sep-27-24 03:36PM	Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims (Yahoo Finance Video) -10.62%
10:10AM	Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims (Investopedia)
Sep-26-24 06:15PM	Cassava Sciences Resolves SEC Investigation (GlobeNewswire)
Sep-24-24 08:30AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire) +9.54%
Sep-09-24 08:30AM	Cassava Sciences Names Rick Barry as Chief Executive Officer (GlobeNewswire)
Sep-03-24 08:31AM	Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 10:44PM	Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks (Insider Monkey)
08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-08-24 08:00AM	Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (GlobeNewswire) -13.84%
Aug-06-24 10:00AM	Cassava Sciences News: Why Is SAVA Stock Trending Today? (InvestorPlace) -13.08%
Aug-05-24 09:01AM	Cassava Sciences Mourns the Death of Board Member Sanford Sandy Robertson (GlobeNewswire) +20.51%
Aug-01-24 08:30AM	Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET (GlobeNewswire) +5.72%
Jul-30-24 08:15AM	Cassava Sciences Announces Expansion of Open-Label Extension Trials (GlobeNewswire)
Jul-17-24 12:26PM	SOUN Stock: Sports Bar Chain Rolls Out Voice Tech From SoundHound AI (InvestorPlace) -29.27%
08:00AM	Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives (GlobeNewswire)
Jul-08-24 04:45PM	3 Healthcare Stocks to Sell in July Before They Crash & Burn (InvestorPlace) +17.38%
Jul-05-24 07:30AM	3 Biotech Stocks to Sell in July Before They Crash & Burn (InvestorPlace) -5.15%
Jul-04-24 07:47AM	Jim Cramer's Latest Stock Portfolio: Top 10 Recommendations (Insider Monkey)
Jul-01-24 03:54PM	Cassava forms committee after US probe, researcher fraud (Yahoo Finance Video)
01:30PM	Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences (The Wall Street Journal)
11:20AM	Planet Labs Layoffs 2024: What to Know About the Latest Planet Job Cuts (InvestorPlace)
10:40AM	SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud (InvestorPlace)
Jun-28-24 06:14PM	Cassava Sciences Adviser Indicted on Fraud Charges (The Wall Street Journal) -34.83%
03:58PM	Cassava Sciences Issues Statement on Former Science Advisor (GlobeNewswire)
Jun-27-24 03:38PM	Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
May-23-24 09:55AM	Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
May-10-24 08:53PM	SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam (GlobeNewswire)
May-08-24 11:00AM	Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution (GlobeNewswire)
May-01-24 09:10AM	Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ (GlobeNewswire)
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-15-24 09:20AM	Redemption Date Announced for Warrants (GlobeNewswire) -12.04%
Mar-25-24 09:13AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire)
Mar-13-24 10:45AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava (PR Newswire)
Mar-04-24 09:15AM	Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference (GlobeNewswire)
Feb-28-24 09:14AM	Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-23-24 11:30AM	CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Feb-08-24 10:39AM	Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial (InvestorPlace)
Feb-07-24 09:08AM	No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months (GlobeNewswire) +7.35%
Feb-05-24 02:35PM	Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-05-24 11:46AM	New SAVAW Warrants Are Trading After Cassava Sciences' Distribution (InvestorPlace)
09:12AM	Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool)
Dec-15-23 06:06PM	Why Cassava Sciences Stock Zoomed 21% Higher This Week (Motley Fool)
Dec-13-23 11:10AM	Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days (Investor's Business Daily)
Dec-12-23 02:02PM	Why Is Cassava Sciences (SAVA) Stock Up 15% Today? (InvestorPlace) +5.96%
09:13AM	Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-08-23 07:31PM	Why Cassava Sciences Stock Soared Today (Motley Fool) +17.37% +13.57%
Dec-07-23 04:01PM	Cassava Sciences Appoints Three New Members to its Board of Directors (GlobeNewswire)
Nov-14-23 09:53PM	7 High-Risk, High-Reward Stocks for the Extreme Contrarian (InvestorPlace) +13.90%
Nov-07-23 09:39AM	Cassava Sciences Inc (SAVA) Reports Q3 2023 Financial Results (GuruFocus.com)
09:01AM	Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-06-23 09:15AM	Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease (GlobeNewswire) -5.81%
Oct-31-23 08:15AM	1 Big Red Flag to Fear When a Stock Is Down (Motley Fool) +6.39%
Oct-25-23 09:15AM	MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA) (GlobeNewswire) +25.80%
Oct-19-23 09:59AM	7 Stocks That Are Heading for a Train Wreck (InvestorPlace) +5.32%
Oct-16-23 07:01PM	Is This The End Of Naked Short Selling? (Oilprice.com) -14.94% +13.21%
05:26PM	SAVA Stock Continues to Plunge on Misconduct Allegations (InvestorPlace)
Oct-13-23 03:29PM	Cassava Sciences Adviser Found to Have Committed Egregious Misconduct (The Wall Street Journal) -15.28%
03:29PM	Alzheimers Researcher Found to Have Committed Misconduct (The Wall Street Journal)
12:45PM	Why Cassava Sciences Stock Is Tanking Today (Motley Fool)
11:21AM	SAVA Stock Alert: Cassava Sciences Addresses Leaked Report (InvestorPlace)
Oct-12-23 11:43PM	Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press (GlobeNewswire)
Oct-06-23 03:13PM	Why Shares of Cassava Sciences Soared This Week (Motley Fool)
Oct-05-23 09:15AM	Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY (GlobeNewswire)

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cook Robert Christopher	Chief Operating & Legal Office	Sep 30 '25	Buy	2.91	13,725	39,940	13,725	Oct 02 04:44 PM
Barry Richard	President & CEO	Sep 22 '25	Buy	2.28	7,172	16,352	714,675	Sep 23 04:06 PM
Barry Richard	President & CEO	Sep 18 '25	Buy	2.24	190,633	426,424	660,195	Sep 22 04:07 PM
Barry Richard	President & CEO	Sep 19 '25	Buy	2.29	47,308	108,319	707,503	Sep 22 04:07 PM
Kupiec James William	Chief Medical Officer	Nov 29 '24	Sale	3.87	4,000	15,480	0	Dec 03 04:18 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Option Exercise	1.18	50,000	59,000	71,300	Dec 03 04:16 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Sale	3.86	59,800	230,828	11,500	Dec 03 04:16 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Sale	3.82	2,000	7,640	0	Dec 03 04:16 PM
Schoen, Eric J. (SAVA)	Officer	Nov 29 '24	Proposed Sale	3.82	2,000	7,640		Dec 02 05:14 PM
Schoen Eric	Officer	Nov 29 '24	Proposed Sale	3.86	59,800	230,966		Nov 29 03:33 PM

Open in Screener

SRPT

Sarepta Therapeutics Inc

Oct 07 • 09:30AM ET

23.22

-0.05 -0.19 %

Healthcare • Biotechnology • USA • NASD

SRPT Sarepta Therapeutics Inc daily Stock Chart

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJR XBI VTI FBT VB VBK SPSM VXF IJT IBB

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	5.50%	Shs Outstand	97.71M	Perf Week	20.47%
Market Cap	2.27B	Forward P/E	10.22	EPS next Y	2.27	Insider Trans	0.00%	Shs Float	92.34M	Perf Month	31.90%
Enterprise Value	2.82B	PEG	-	EPS next Q	-0.64	Inst Own	89.20%	Short Float	21.96%	Perf Quarter	19.85%
Income	-57.96M	P/S	0.91	EPS this Y	-289.04%	Inst Trans	-7.62%	Short Ratio	1.67	Perf Half Y	-55.70%
Sales	2.48B	P/B	1.67	EPS next Y	155.10%	ROA	-1.63%	Short Interest	20.28M	Perf YTD	-80.91%
Book/sh	13.89	P/C	2.84	EPS next 5Y	4.24%	ROE	-4.76%	52W High	138.81 -83.28%	Perf Year	-80.45%
Cash/sh	8.19	P/FCF	-	EPS past 3/5Y	- -	ROIC	-2.14%	52W Low	10.41 122.90%	Perf 3Y	-78.82%
Dividend Est.	-	EV/EBITDA	50.12	Sales past 3/5Y	39.42% 37.94%	Gross Margin	77.63%	Volatility	8.68% 6.60%	Perf 5Y	-83.57%
Dividend TTM	-	EV/Sales	1.14	EPS Y/Y TTM	-221.56%	Oper. Margin	-0.04%	ATR (14)	1.31	Perf 10Y	-35.99%
Dividend Ex-Date	-	Quick Ratio	1.81	Sales Y/Y TTM	64.89%	Profit Margin	-2.34%	RSI (14)	70.14	Recom	2.85
Dividend Gr. 3/5Y	- -	Current Ratio	2.89	EPS Q/Q	2662.81%	SMA20	21.90%	Beta	0.49	Target Price	23.35
Payout	0.00%	Debt/Eq	1.00	Sales Q/Q	68.38%	SMA50	24.30%	Rel Volume	0.32	Prev Close	23.26
Employees	1372	LT Debt/Eq	1.00	Earnings	Aug 06 AMC	SMA200	-58.92%	Avg Volume	12.11M	Price	23.22
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	127.08% 15.16%	Trades		Volume	193,730	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold
Jun-20-25	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-25	Downgrade	TD Cowen	Buy → Hold	$24
Jun-17-25	Initiated	Wolfe Research	Peer Perform

Show Previous Ratings

Oct-03-25 02:14PM	Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results (Insider Monkey)
08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress (Business Wire)
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch) +15.68%
05:31AM	FDA leaders are acting political, says ex-agency chief counsel (Pharmaceutical Technology)
Sep-30-25 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:38AM	Loading…
Sep-28-25 04:38AM	Street Calls of the Week (Investing.com)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-05-25 09:30AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
09:00AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year (Business Wire)
Sep-03-25 07:27AM	Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results (Insider Monkey)
Aug-28-25 08:21AM	Cell and gene therapies on correction course but not sinking (Pharmaceutical Technology)
Aug-26-25 06:15PM	Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Aug-23-25 11:33AM	Credit Fuels the AI Boom and Fears of a Bubble (Bloomberg)
Aug-21-25 12:13PM	Walmart weighs on Dow, Sarepta debt restructuring (Yahoo Finance Video)
09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
07:00AM	Loading…
07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
06:56AM	Sarepta pushes off debt payments in bid to regain financial footing (BioPharma Dive)
Aug-20-25 11:37PM	Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" (Insider Monkey)
11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-18-25 09:03AM	Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights - Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
07:00AM	How the Moms and Dads of Patients Won Sareptas Drug a Reprieve (Bloomberg)
Aug-15-25 09:15AM	Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT (PR Newswire) +7.44%
Aug-14-25 09:00PM	Lightning Round: I don't have a positive outlook on Sarepta, says Jim Cramer (CNBC TV)
04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily)
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +8.51%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)
Aug-12-25 03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
07:17AM	Loading…
07:17AM	Prasads shock FDA return reignites regulatory uncertainty (Pharmaceutical Technology)
Aug-11-25 04:40PM	These Stocks Moved the Most Today: C3.ai, Coinbase, Monday.com, Avantor, Tegna, Nvidia, Albemarle, and More (Barrons.com)
03:24PM	Leadership Turmoil at FDA Adds to Difficult Stretch for Biotech Investors (Barrons.com)
11:06AM	These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Avantor, Tegna, Nvidia, Albemarle, and More (Barrons.com)
11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:22AM	Wall St futures steady, chip stocks slip on China sales deal (Reuters)
06:09AM	Nvidia and AMD shares dip, and other movers (MarketWatch)
05:26AM	These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More (Barrons.com)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
04:00AM	As gene therapies falter on the market, this biopharma is aiming to defy the odds (Pharma Voice)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +10.46%
09:29AM	Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries (Zacks)
Aug-06-25 07:00PM	Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:45PM	Sarepta Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments (Business Wire)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks) +7.48%
08:30AM	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer (GlobeNewswire)
Jul-31-25 06:22PM	493 employees laid off at biopharmaceutical company with operations in Andover (Andover Townsman, Mass.)
01:53PM	George Tidmarsh to sub in as FDA CBER head following Prasads shock exit (Pharmaceutical Technology)
10:00AM	Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:48AM	Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results (Business Wire)
06:38AM	Markets Are Being Driven by AI, Not the Fed. Where Stocks Go From Here. (Barrons.com)
04:05AM	Stock Market News, July 30, 2025: U.S., Korea Reach Trade Deal; Powell Signals Reluctance to Cut Rates (The Wall Street Journal)
Jul-30-25 01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com) +5.81%
10:00AM	Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)
09:36AM	Stocks to Watch Wednesday: Hershey, GE HealthCare, Starbucks, SoFi (The Wall Street Journal)
06:02AM	Starbucks stock jumps after earnings, and other early market movers (MarketWatch)
05:23AM	Stocks to Watch Wednesday: Visa, Starbucks, Meta, SoFi (The Wall Street Journal)
Jul-29-25 05:32PM	Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments (Investor's Business Daily) +14.21%
05:11PM	These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More (Barrons.com)
03:38PM	Sarepta Therapeutics, Inc. (SRPT): "You Don't Court Homicide," Says Jim Cramer (Insider Monkey)
03:01PM	These Stocks Are Moving the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More (Barrons.com)
02:47PM	Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault. (MarketWatch)
01:54PM	Squawk Pod: Commerce Secretary Lutnick & a midtown tragedy - 07/29/25 Audio Only (CNBC TV)
10:49AM	PayPal, Sarepta, JetBlue: Trending Tickers (Yahoo Finance Video)
10:16AM	Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume (Investopedia)
07:21AM	Sarepta shares rebound after shipments of gene therapy Elevidys resume in US (Reuters)
06:50AM	Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars (Yahoo Finance)
05:27AM	These Stocks Are Moving the Most Today: Sarepta, Whirlpool, VeriSign, Cadence Design, Exelixis, UnitedHealth, and More (Barrons.com)
05:22AM	Sarepta surges, Whirlpool sinks, and other early market movers (MarketWatch)
05:01AM	Sarepta Stock Just Soared 45%. Here's Why. (Barrons.com)
Jul-28-25 06:38PM	Sarepta will resume gene therapy shipments after FDA review of recent patient death (Associated Press Finance) +16.18%
05:17PM	Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD (Investing.com)
05:09PM	FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy (Business Wire)
04:55PM	Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap (Bloomberg)
04:34PM	Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe (Yahoo Finance Video)
11:11AM	BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50 (Insider Monkey)
09:54AM	Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained. (Barrons.com)
08:48AM	FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys (Benzinga)
07:30AM	Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics (Business Wire)
05:46AM	Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained. (Barrons.com)
Jul-25-25 07:51PM	Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS (Business Wire) -7.38%
04:16PM	Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe (Investor's Business Daily)
11:30AM	CHMP rejects Elevidys in latest setback for Sarepta (Pharmaceutical Technology)
11:05AM	Stock Market Today: S&P 500 Notches Fifth Consecutive Record Close as Vanguard, Goldman Warn On Growth (TheStreet)
08:34AM	Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union (Business Wire)
07:35AM	Sarepta stock falls after Elevidys fails to get backing by EU regulators (Investing.com)
07:08AM	SRPT STOCK NOTICE: Sarepta Therapeutics, Inc. Investors are Notified the Company is being Sued for Fraud and to Contact BFA Law by August 25 (Newsfile)
Jul-24-25 04:29PM	The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.' (Investor's Business Daily)
04:04PM	Stocks Close at Record as Alphabet Fuels AI Hopes: Markets Wrap (Bloomberg)
10:37AM	Sarepta Therapeutics (SRPT): "They Should Be Prosecuted," Says Jim Cramer (Insider Monkey)
07:40AM	Is This Stock a Buy After Soaring by 20% in 1 Day? (Motley Fool)
Jul-23-25 05:07PM	Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause (Yahoo Finance)
03:57PM	Sarepta Therapeutics, Inc. (SRPT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
09:41AM	Shopify and Unity downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics (Business Wire)
03:00AM	Sarepta's Troubles Show Risk, Investor Opportunity in Biotech Convertible Bonds (Barrons.com)
Jul-22-25 04:05PM	Sarepta Makes A 'Painful' Decision. Will It Help Rebuild Investors' Confidence? (Investor's Business Daily)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM
Estepan Ian Michael	Chief Financial Officer	Jan 29 '25	Option Exercise	12.00	15,800	189,600	49,496	Jan 31 08:30 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Option Exercise	13.71	10,500	143,955	33,340	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Sale	124.84	10,500	1,310,820	22,840	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM

SAVA

Cassava Sciences Inc

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience